表观遗传药物对体细胞核移植胚胎发育的促进作用

Progress on Epigenetic Drugs in Development of Somatic Cell Nuclear Transfer Embryos

体细胞核移植(somatic cell nuclear transfer,SCNT)是利用卵母细胞胞质中的重编程物质对高度分化体细胞核进行重编程作用使其恢复全能性并发育为新个体的技术。在SCNT过程中,表观遗传修饰参与卵母细胞的重编程,如DNA甲基化修饰和组蛋白的翻译后修饰。这些重编程的异常修饰会对SCNT胚胎的发育产生不良影响。表观遗传药物,如DNA甲基转移酶抑制剂和组蛋白去乙酰基酶抑制剂,可改善表观遗传修饰的异常现象,促进体细胞核移植重构胚的重编程。该文对SCNT胚胎重编程过程中的异常表观遗传修饰以及近年来报道的表观遗传相关药物进行综述,并进一步探讨了这些药物对SCNT胚胎发育的促进作用。

Somatic cell nuclear transfer （SCNT） is a technology, which makes reprogramming of highly differentiated somatic cell nuclear by making use of cytoplasmic reprogramming material in the oocyte, finally restores：the totipotency and develops into a new number. In SCNT, epigenetic modifications participate in reprogramming of oocyte, such as modifications of DNA methylation patterns and histone modification after translation, their abnormal expression has adverse impacts on the development of SCNT embryos. Epigenetic drugs, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, can improve the abnormal epigenetic modifications and promote the reprogramming of SCNT embryos. This paper summarizes the abnormal epigenetic modifications in the process of SCNT embryonic development as well as the progress of epigenetic drugs. The effects of the drugs on SCNT embryos development were discussed further.